Cargando…

Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection

There are currently no FDA-approved therapeutics available to treat Rift Valley fever virus (RVFV) infection. In an effort to repurpose drugs for RVFV treatment, a library of FDA-approved drugs was screened to determine their ability to inhibit RVFV. Several drugs from varying compound classes, incl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Benedict, Ashwini, Bansal, Neha, Senina, Svetlana, Hooper, Idris, Lundberg, Lindsay, de la Fuente, Cynthia, Narayanan, Aarthi, Gutting, Bradford, Kehn-Hall, Kylene
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2015
Materias:	Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4495339/ https://www.ncbi.nlm.nih.gov/pubmed/26217313 http://dx.doi.org/10.3389/fmicb.2015.00676

Ejemplares similares

Alterations in the host transcriptome in vitro following Rift Valley fever virus infection
por: Pinkham, Chelsea, et al.
Publicado: (2017)

p53 Activation following Rift Valley Fever Virus Infection Contributes to Cell Death and Viral Production
por: Austin, Dana, et al.
Publicado: (2012)

The Use of NanoTrap Particles as a Sample Enrichment Method to Enhance the Detection of Rift Valley Fever Virus
por: Shafagati, Nazly, et al.
Publicado: (2013)

The Use of Nanotrap Particles in the Enhanced Detection of Rift Valley Fever Virus Nucleoprotein
por: Shafagati, Nazly, et al.
Publicado: (2015)

Combination Kinase Inhibitor Treatment Suppresses Rift Valley Fever Virus Replication
por: Bell, Todd M., et al.
Publicado: (2018)

Phosphoproteomic analysis reveals Smad protein family activation following Rift Valley fever virus infection
por: de la Fuente, Cynthia, et al.
Publicado: (2018)

Correction: Phosphoproteomic analysis reveals Smad protein family activation following Rift Valley fever virus infection
por: de la Fuente, Cynthia, et al.
Publicado: (2018)

Modeling the Tertiary Structure of the Rift Valley Fever Virus L Protein
por: Gogovi, Gideon K., et al.
Publicado: (2019)

Reverse-Phase Phosphoproteome Analysis of Signaling Pathways Induced by Rift Valley Fever Virus in Human Small Airway Epithelial Cells
por: Popova, Taissia G., et al.
Publicado: (2010)

Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016)

Repurposing of FDA-approved drugs against cancer – focus on metastasis
por: Ozsvári, Béla, et al.
Publicado: (2016)

Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle
por: Huang, Yue, et al.
Publicado: (2022)

Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir?
por: Zaidi, Asifa, et al.
Publicado: (2015)

Repurposing of existing FDA approved drugs for Neprilysin inhibition: An in-silico study
por: Sankhe, Runali, et al.
Publicado: (2021)

Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer
por: Bibby, Becky A. S., et al.
Publicado: (2021)

REPURPOSING OF FDA APPROVED COMPOUNDS TO INHIBIT OSM/OSMR SIGNALING IN GLIOBLASTOMA
por: Lotfipour, Farzaneh, et al.
Publicado: (2023)

Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans
por: Kim, Kevin, et al.
Publicado: (2015)

Repurposing FDA-approved sulphonamide carbonic anhydrase inhibitors for treatment of Neisseria gonorrhoeae
por: Abutaleb, Nader S., et al.
Publicado: (2021)

Hydrogel-Based Pre-Clinical Evaluation of Repurposed FDA-Approved Drugs for AML
por: James, Jenna R., et al.
Publicado: (2023)

Impact of Nutrition or FDA-Approved Medicine Repurposing on Metabolic Syndrome and Diabetic Complications
por: Cai, Lu
Publicado: (2023)

Efficacy of FDA-Approved Anti-Inflammatory Drugs Against Venezuelan Equine Encephalitis Virus Infection
por: Risner, Kenneth, et al.
Publicado: (2019)

Modulation of GSK-3β Activity in Venezuelan Equine Encephalitis Virus Infection
por: Kehn-Hall, Kylene, et al.
Publicado: (2012)

The Role of IKKβ in Venezuelan Equine Encephalitis Virus Infection
por: Amaya, Moushimi, et al.
Publicado: (2014)

Can an FDA-Approved Alzheimer’s Drug Be Repurposed for Alleviating Neuronal Symptoms of Zika Virus?
por: Sirohi, Devika, et al.
Publicado: (2017)

Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
por: Kandeel, Mahmoud, et al.
Publicado: (2020)

Accelerating the repurposing of FDA-approved drugs against coronavirus disease-19 (COVID-19)
por: De Vita, Simona, et al.
Publicado: (2020)

Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells
por: Jones, Dylan, et al.
Publicado: (2022)

Multi-Faceted Proteomic Characterization of Host Protein Complement of Rift Valley Fever Virus Virions and Identification of Specific Heat Shock Proteins, Including HSP90, as Important Viral Host Factors
por: Nuss, Jonathan E., et al.
Publicado: (2014)

The Pathogenesis of Rift Valley Fever
por: Ikegami, Tetsuro, et al.
Publicado: (2011)

Rift Valley Fever Encephalitis
por: Alrajhi, Abdulrahman A., et al.
Publicado: (2004)

Rift Valley Fever in Chad
por: Ringot, David, et al.
Publicado: (2004)

Repurposing the FDA-Approved Pinworm Drug Pyrvinium as a Novel Chemotherapeutic Agent for Intestinal Polyposis
por: Li, Bin, et al.
Publicado: (2014)

QUADrATiC: scalable gene expression connectivity mapping for repurposing FDA-approved therapeutics
por: O’Reilly, Paul G., et al.
Publicado: (2016)

Computational Cell Cycle Profiling of Cancer Cells for Prioritizing FDA-Approved Drugs with Repurposing Potential
por: Lo, Yu-Chen, et al.
Publicado: (2017)

Large-Scale Drug Screen Identifies FDA-Approved Drugs for Repurposing in Sickle-Cell Disease
por: Cannon, Matthew, et al.
Publicado: (2020)

FDA Approved Drugs Repurposing of Toll-Like Receptor4 (TLR4) Candidate for Neuropathy
por: Zali, Hakimeh, et al.
Publicado: (2019)

Repurposing FDA Approved Drugs as JNK3 Inhibitor for Prevention of Neuroinflammation Induced by MCAO in Rats
por: Zulfiqar, Zikra, et al.
Publicado: (2020)

Repurposing FDA‐Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease
por: Xu, Chenshu, et al.
Publicado: (2020)

Geroscience‐guided repurposing of FDA‐approved drugs to target aging: A proposed process and prioritization
por: Kulkarni, Ameya S., et al.
Publicado: (2022)

Repurposing Screens of FDA-Approved Drugs Identify 29 Inhibitors of SARS-CoV-2
por: Ku, Keun Bon, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lae1b0tgel7tsj7rjkerpkfuj2